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Abstract
Background: Doxorubicin is a chemotherapeutic agent used in a wide spectrum of cancers.
However, cardiotoxic effects have limited its clinical use. The early detection of doxorubicin-
-induced cardiotoxicity is crucial. The purpose of our study was to assess values of Doppler and
tissue Doppler imaging (TDI)-derived myocardial performance index (MPI) in adult cancer
patients receiving doxorubicin treatment.
Methods: A total of 45 patients underwent echocardiographic examinations before any
doxorubicin had been administered and then after doxorubicin. Doppler and TDI-derived MPI
of left ventricular (LV) were determined in the evaluation of cardiotoxicity. Additionally, TDI-
-derived MPI of right ventricular (RV) was determined.
Results: All patients underwent control echocardiographic examination after mean 5 ± 1.7
months. The LV MPI obtained by both Doppler and TDI were increased after doxorubicin
treatment (0.56 ± 0.11, 0.61 ± 0.10, p = 0,005 vs 0.51 ± 0.09, 0.59 ± 0.09, p = 0.001,
respectively). There was no correlation between Doppler-derived MPI and cumulative
doxorubicin dose (coefficient of correlation 0.11, p = 0.6). TDI-derived MPI was correlated
with cumulative doxorubicin dose (coefficient of correlation 0.35, p = 0.015), but this
correlation is weak (r = 0.38). The study population was divided into two groups according to
doxorubicin dose (below and above 300 mg level). There was a moderate correlation between
TDI-derived MPI and less than 300 mg of doxorubicin dose (coefficient of correlation 0.51,
p = 0.028). However, Doppler-derived MPI was not correlated with less than 300 mg of
doxorubicin dose (coefficient of correlation 0.38, p = 0.123). Also, there was no significant
change in the TDI-derived RV-MPI (0.49 ± 0.14, 0.50 ± 0.12, p = 0.56).
Conclusions: TDI-derived MPI is a useful parameter and an early indicator compared with
Doppler-derived MPI in the detection of cardiotoxicity during the early stages. Also, doxorubicin
administration does not affect RV function. (Cardiol J 2012; 19, 4: 363–368)
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Introduction
Anthracyclines are effective agents used in the
treatment of hematological malignancies and solid
tumors [1]. However, the cardiotoxic effects of an-
thracyclines have limited their clinical use. Increased
free radical production and reduced myocardial anti-
oxidants are believed to be the major mechanisms
responsible for cardiotoxicity [2, 3]. More common-
ly, anthracyclines cause progressive chronic car-
diotoxicity resulting in heart failure, which general-
ly presents within 1 year of treatment [4]. Cardiotoxi-
city is related to cumulative dosage. However,
sensitivity to this severe side-effect is usually indi-
vidual and a subgroup of patients shows signs of car-
diomyopathy even at low anthracycline doses [5].
The early detection of anthracycline cardiotoxi-
city is very important because it may be useful in
the prevention of heart failure. Therefore, evalua-
tion of cardiac dysfunction is critical before changes
become irreversible in the myocardium during treat-
ment. Left ventricular ejection fraction (LVEF) is the
most commonly used echocardiographic parameter. It
has been the main indicator of cardiac dysfunction and
a powerful predictor of mortality [6]. However, im-
pairment in LVEF is often detected only after con-
siderable myocyte loss has taken place.
The myocardial performance index (MPI) has
been described as a noninvasive Doppler measure-
ment of global (systolic and diastolic) ventricular
function [7]. MPI may be calculated using the time
intervals obtained by both Doppler and tissue Dop-
pler imaging (TDI) [8]. MPI is defined as the ratio
of the sum of isovolumic relaxation time (IRT) and
isovolumic contraction time (ICT), over the ejec-
tion time (ET). In the evaluation of LV performance,
TDI is more reliable than Doppler, given that it is
less influenced by loading conditions and heart rate
changes [7]. Although TDI-derived MPI is more
reliable than Doppler-derived MPI, it has not been
used to evaluate anthracycline cardiotoxicity in
adult patients in the previous studies so far.
The aim of the current study was to assess
values of MPI obtained by tissue Doppler imaging
and MPI obtained by Doppler in adult cancer pa-
tients receiving doxorubicin therapy.
Methods
Study design
Forty-five patients requiring doxorubicin-con-
taining chemotherapy for solid or hematological
malignancy were enrolled in the study. All patients
gave written informed consent prior to participation
in the study. The local ethics committee approved
the study and all patients provided informed consent.
Patients were excluded if they had a history of
coronary artery disease, systemic hypertension,
prior use of anthracycline therapy, prior or addition-
al mediastinal radiotherapy, chronic renal failure,
chronic obstructive lung disease, and any rhythm
other than normal sinus rhythm. In addition, we
excluded patients having the following echocardio-
graphic criteria: (a) abnormal LV systolic function
(EF £ 50% according to modified Simpson’s me-
thod); (b) poor echo image quality; (c) moderate or
severe valvular heart disease.
Blood pressure, heart rate, and demographic
characteristics of the patients were recorded. The
study was designed to assess each patient by
echocardiography before they received doxorubicin
and about 5 months after completion of their che-
motherapy.
Echocardiography
The patients were evaluated before and after
(mean of 5 months after the last cycle of the chemo-
therapy) doxorubicin therapy, using an Advanced
Technology Laboratory 5000 echocardiography de-
vice with a 2–4 MHz transducer, according to re-
commendations of the American Society of Echocar-
diography. LVEF was estimated with Simpson’s
modified biplane methods. The mitral inflow veloci-
ty was recorded by placing the sample volume be-
tween the tips of the mitral leaflets from the apical
4-chamber view. The LV outflow pattern was record-
ed from the apical 5-chamber view by placing sam-
ple volume just below the aortic valve. Each Dop-
pler measurement was calculated from an average
of five consecutive cardiac cycles at a sweep speed
of 100 mm/s. Doppler time intervals were measured
from mitral inflow and LV outflow tract velocity.
The pulsed-wave TDI was performed by acti-
vating the tissue Doppler function in the same
echocardiography machine. The filter settings were
kept low, and gains were adjusted at the minimal
optimal level to minimize noise and eliminate the
signals produced by the transmitral flow. A 3.5-mm
sample volume was used. In the apical 4-chamber
view, the TDI cursor was placed at the septal and
lateral sides of the mitral annulus, and right ven-
tricular (RV) free wall side of the tricuspid annulus
in such a way that the annulus moved along the
sample volume line. In the apical 2-chamber view,
the TDI cursor was placed at the anterior and infe-
rior sides of the mitral annulus in the same man-
ner. A Doppler velocity range of –15 to 15 cm/s was
selected for this study. In the TDI, the systolic ve-
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locity duration was measured as ET, whereas the
time between the end of the systolic velocity and the
beginning of early diastolic velocity was recorded as
IRT, and the time between the end of the late dias-
tolic velocity and the beginning of systolic velocity
was recorded as ICT (Fig. 1). The MPI was also cal-
culated using the same parameters obtained by Dop-
pler method or TDI [MPI = (IRT + ICT)/ET]. The
mean values of these parameters were calculated
with values obtained from 4 different LV sites.
Statistical analysis
Statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS) for
Windows, version 15.0. All data were expressed as
mean values ± SD. All parameters before and after
chemotherapy were compared by paired t tests.
Correlations between variables were tested by
means of bivariate correlation testing. Analysis of
the differences of the measurements by Doppler
and by TDI methods was performed according to
the Bland-Altman technique. A p-value < 0.05 was
considered statistically significant.
Results
Baseline characteristics of the study group are
listed in Table 1. The mean cumulative doxorubicin
dose was 268.3 ± 49.9 mg/m2 (range: 150–360 mg).
All patients underwent control echocardiographic
examination after mean 5 ± 1.7 months. All patients
completed the planned treatment. Symptomatic
diastolic heart failure developed in one patient. The
rest of the patients tolerated the treatment well.
No significant changes in LVEF were observed.
The LV-MPI and LV Sm obtained by both Doppler
and TDI were impaired after chemotherapy (Table 2).
There was no correlation between Doppler-derived
MPI and cumulative doxorubicin dose (coefficient
of correlation 0.11, p = 0.6). On the other hand,
TDI-derived MPI was correlated with cumulative
doxorubicin dose (coefficient of correlation 0.35,
p = 0.015) but this correlation is weak. The study
population was divided into two groups according to
doxorubicin dose (below and above 300 mg level). In
correlation analysis, there was a moderate correla-
tion between TDI-derived MPI and less than 300 mg
of doxorubicin dose (coefficient of correlation 0.51,
p = 0.028). However, Doppler-derived MPI was not
correlated with less than 300 mg of doxorubicin dose
(coefficient of correlation 0.38, p = 0.123).
Besides, there was no significant change in the
RV-MPI and RV Sm obtained by TDI after therapy
(Table 2). The comparison of MPI obtained by Dop-
pler and TDI was tested by the Bland-Altman meth-
od. Plots figures obtained by Bland-Altman were
shown to be in compliance with one another pre-
treatment and post-treatment (Figs. 2A, B, respec-
tively). However, a larger limit agreement was
found. For this reason, small changes in MPI could
not be correctly detected by conventional MPI.
Discussion
Significant increase has been determined in
LV-MPI obtained by Doppler and TDI. Moreover,
the current study demonstrated an obvious corre-
lation between doxorubicin dose and TDI-derived
Table 1. Study group baseline demographics.
Variable Value
Gender (female/male) 37:8
Age [years] 50.1 ± 13.6
Type of anthracycline Doxorubicine
Dose of anthracycline [mg/m2] 268.3 ± 49.9
Number of cyclus 4.8 ± 0.9
Time of control echocardiography [m] 5 ± 1.7
Body surface area 1.71 ± 0.11
Type of cancer:
 Breast 33
 Non-Hodgkins Lymphoma 5
 Hodgkins Lymphoma 4
 Leiomyosarcoma 3
Figure 1. The measurement of the TDI-derived time
intervals. The MPI is calculated by the formula
[(ICT + IRT)/ET].
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MPI. However, there was no significant correla-
tion between doxorubicin dose and Doppler-de-
rived MPI.
Although doxorubicin is a highly effective an-
tineoplastic agent, its early and late stage cardioto-
xic effects limit its use. Because of the high morta-
lity and insufficiency of treatment options for pa-
tients who develop cardiomyopathy, early diagnosis
of cardio toxicity is very important. In a series of
more than 3,900 patients treated with anthracycline,
Von Hoff et al. [4] noted that congestive heart fail-
ure secondary to anthracycline-induced chronic car-
diomyopathy occurred 0 to 231 days after the com-
pletion of doxorubicin therapy. Already, it is known
that the incidence of congestive heart failure se-
condary to doxorubicin-induced cardiomyopathy de-
pends on the cumulative dose of the drug.
Lee et al. [9] demonstrated that abnormalities
of diastolic function in adult patients resulted when
patients received lower doses of anthracycline than
doses producing significant changes in systolic func-
tion. Marchandise et al. [10] found a prolongation
of the IRT (from 65 ms to 86 ms) and a reduction in
E velocity (from 60 ms to 49 ms) in anthracycline-
treated adults. In agreement with previous stud-
ies, we also found a significant decrease in E ve-
locity and E\A ratio, as well as significant prolon-
gation in IRT.
The MPI has been shown to correlate well with
other invasive and noninvasive measures of LV
Figure 2. Bland-Altman plot of the difference between the Doppler-derived MPI and tissue Doppler-derived MPI. Solid
and dashed lines, the mean (average) ± 1.96 SD, respectively. A. Pre-treatment period; B. Post-treatment period.
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Table 2. Standard and tissue Doppler echocardiographic measurements before and after doxorubicine
treatment.
Before treatment After treatment P
Standard echo
Left ventricular ejection fraction 61,50 ± 2,85 60,94 ± 2,45 NS
E velocity 69.44 ± 14.83 63.02 ± 13.85 0.001
E/A ratio 0.99 ± 0.39 0.91 ± 0.27 0.03
Isovolumetric relaxation time 95.15 ± 21.11 103.51 ± 18.56 0.004
LV-MPI 0.56 ± 0.11 0.61 ± 0.10 0.005
Tissue Doppler
LV-MPI 0.51 ± 0.09 0.59 ± 0.09 0.001
LV Sm [cm/sn] 9.85 ± 1.45 8.74 ± 1.29 0.001
RV-MPI 0.49 ± 0.14 0.50 ± 0.12 NS
RV Sm [cm/sn] 14.07 ± 2.72 13.56 ± 2.60 NS
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function in adults [11]. The MPI correctly estimates
morbidity and mortality in patients with cardiac
amyloidosis, primary pulmonary hypertension,
idiopathic dilated cardiomyopathy, and acute myo-
cardial infarction [12–16]. In previous studies, it has
been shown that Doppler-derived MPI is a useful
method and parameter for the detection of anthra-
cycline cardiotoxicity [17, 18]. Eidem et al. [17] have
detected an increase of Doppler-derived MPI in
children treated with anthracyclines. The authors
indicated that Doppler-derived MPI is a more sen-
sitive parameter detecting for subclinical cardioto-
xicity than conventional echocardiographic measures
such as E/A ratio, and IRT. In another study, Senju
et al. [19] examined 23 patients during anthracycline
treatment. They found that change in the Doppler-
-derived MPI is a more sensitive indicator of early
cardiotoxicity than LVEF and that there was a cor-
relation between doxorubicin dose and Doppler-
-derived MPI. In our study, although Doppler-
-derived MPI has significantly increased, it did not
correlate with doxorubicin dose. There may be two
possible reasons of this: first, post-treatment
echocardiographic evaluation was performed dur-
ing earlier stages than in the other studies; second,
the doxorubicin dose was lower in our study than
in previous studies.
To our knowledge, this study is the first time
that TDI-derived MPI has been used for detection
of cardiotoxicity after doxorubicin therapy in adult
patients. In our study, we found a rise of TDI-de-
rived MPI after therapy and this rise correlated
doxorubicin dose, contrary to Doppler-derived MPI.
This result shows that TDI-derived MPI is more
sensitive and a more useful parameter than Dop-
pler-derived MPI in detecting subclinical cardioto-
xicity, especially during the early period.
In the literature, there have been few data
about RV functions after doxorubicin therapy. Ei-
dem et al. reported that the Doppler-derived MPI
of RV is not significantly changed in association with
the use of anthracyclines in children [17]. Belham
et al. [20] examined 23 patients during anthracycline
treatment. They found that anthracycline adminis-
tration was significantly associated with an increase
in the Doppler-derived MPI of LV and that there
was no significant change in the Doppler-derived
MPI of RV. The authors concluded that this differ-
ence may have resulted from ventricular function-
al reserve and afterload differences between LV and
RV. In our study, RV functions were evaluated by
the TDI-derived MPI. We showed that TDI-derived
MPI of RV did not significantly change with the use
of doxorubicin. To our knowledge, this finding ob-
tained by TDI-derived MPI is the first to demon-
strate different effects on RV functions associated
with the use of the doxorubicin.
Results of this study have indicated that both
systolic and diastolic dysfunctions of LV may de-
velop during the early stages after even low-dose
doxorubicin therapy. Our study showed that TDI-
-derived MPI is a useful parameter and an early in-
dicator compared with Doppler-derived MPI in the
detection of ventricular dysfunction caused by do-
xorubicin in adult patients. On the other hand, to the
best of our knowledge, this study is the first to show
via TDI method that doxorubicin therapy has nega-
tively affected LV functions but does not affect RV
functions. Further prospective, randomized and pla-
cebo-controlled clinical studies are needed to inves-
tigate the value of TDI-derived MPI in echocardio-
graphic evaluations and the follow-up of the ven-
tricular function in patients with subclinical cardiac
damage.
Limitations of study
First, subclinical or silent coronary artery dise-
ase cannot be excluded in patients without per-
forming coronary angiography. Already, because
most of our patients were young and female, it was
very likely that our patient population had a low in-
cidence of coronary artery disease. Secondly, pre-
viously presented myocardial disease cannot be
excluded, as myocardial histology was not investi-
gated. Thirdly, in our study, increased baseline va-
lue of MPI may be associated with malignancy and
this may have influenced our results. Finally, the
small number of patients and absence of a control
group may also act as another limitation of our
study.
Conflict of interest: none declared
References
1. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy:
Efficacy, safety and pharmacological basis of an intermittent sin-
gle high dose schedule. Cancer, 1974; 33: 19–27.
2. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. An-
thracycline-induced cardiotoxicity: course, pathophysiology, pre-
vention and management. Exp Opin Pharmacother, 2007; 8:
1039–1058.
3. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-
-induced heart failure: mechanism and modulation. Mol Cell
Biochem, 2000; 207: 77–85.
4. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxoru-
bicin-induced congestive heart failure. Ann Intern Med, 1979;
91: 710–717.
5. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of
anthracycline cardiotoxicity: A prospective, blinded, long-term
368
Cardiology Journal 2012, Vol. 19, No. 4
www.cardiologyjournal.org
observational study of outcome in 120 patients. Ann Oncol, 2002;
13: 699–709.
6. Borow KM, Henderson IC, Neuman A et al. Assessment of left
ventricular contractility in patients receiving doxorubicin. Ann
Intern Med, 1983; 99: 750–756.
7. Tei C, Ling LH, Hodge DO et al. New index of combined systolic
and diastolic myocardial performance: A simple and reproducible
measure of cardiac function: A study in normals and dilated car-
diomyopathy. J Cardiol, 1995; 26: 357–366.
8. Ozdemir K, Altunkeser BB, Icli A, Ozdil H, Gok H. New param-
eters in identification of right ventricular myocardial infarction
and proximal right coronary artery lesion. Chest, 2003; 124:
219–226.
9. Lee BH, Goodenday LS, Muswick GJ et al. Alternations in left
ventricular diastolic function with doxorubicin therapy. J Am
Coll Cardiol, 1987; 9: 184–188.
10. Marchandise B, Schroeder E, Bosly A et al. Early detection of
doxorubicin cardiotoxicity: interest of Doppler echocardiogra-
phic analysis of left ventricular filling dynamics. Am Heart J,
1989; 118: 92–98.
11. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Dop-
pler-derived myocardial performance index: correlation with si-
multaneous measurements of cardiac catheterization measure-
ments. J Am Soc Echocardiogr, 1997; 10: 169–178.
12. Tei C, Dujardin KS, Hodge DO et al. Doppler index combining
systolic and diastolic myocardial performance: Clinical value in
cardiac amyloidosis. J Am Coll Cardiol, 1996; 28: 658–664.
13. Yeo TC, Dujardin KS, Tei C et al. Value of a Doppler-derived
index combining systolic and diastolic time intervals in predict-
ing outcome in primary pulmonary hypertension. Am J Cardiol,
1998; 81: 1157–1161.
14. Dujardin KS, Tei C, Yeo TC et al. Prognostic value of a Doppler
index combining systolic and diastolic performance in idiopa-
thic-dilated cardiomyopathy. Am J Cardiol, 1998; 82: 1071–
–1076.
15. Sasao H, Noda R, Hasegawa T et al. Prognostic value of the Tei
index combining systolic and diastolic myocardial performance
in patients with acute myocardial infarction treated by success-
ful primary angioplasty. Heart Vessels, 2004; 19: 68–74.
16. Bruch C, Schmermund A, Marin D et al. Tei-index in patients
with mild-to-moderate congestive heart failure. Eur Heart J,
2000; 21: 1888–1895.
17. Eidem BW, Sapp BG, Suarez CR et al. Usefulness of the myo-
cardial performance index for detection of anthracycline induced
cardiotoxicity in children. Am J Cardiol, 2001; 87: 1120–1122.
18. Ocal B, Oguz D, Karademir S et al. Myocardial performance
index combining systolic and diastolic myocardial performance
in doxorubicin-treated patients and its correlation to conven-
tional echo/Doppler indices. Pediatr Cardiol, 2002; 23: 522–
–527.
19. Senju N, Ikeda S, Koga S et al. The echocardiographic Tei-index
reflects early myocardial damage induced by anthracycline in
patients with hematological malignancies. Heart Vessels, 2007;
22: 393–397.
20. Belham M, Kruger A, Pritchard C. The Tei index identifies
a differential effect on left and right ventricular function with
low-dose anthracycline chemotherapy. J Am Soc Echocardiogr,
2006; 19: 206–210.
